Company intelligence / Profile preview

Sentinal4D

Ownership: Private
Development stage: Preclinical

Overview

Sentinal4D is a spinout from The Institute of Cancer Research (ICR), London, leveraging proprietary AI-driven high-throughput imaging and computational models to accelerate precision oncology drug discovery. The company recently completed its pre-seed funding round and is building out its leadership team. Its approach integrates deep learning with advanced cell omics to provide actionable insights that improve the efficiency and success rate of early-stage drug development.

Therapeutic areas: OncologyPsychiatryImmunologyNeurology
Modalities: Small molecules
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Sentinal4D.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sentinal4D.

Explore the full profile